Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics
EDMONTON, Alberta–(BUSINESS WIRE)–Entos® Pharmaceuticals (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix™ PLV™ technology to develop cures and improve the lives of patients and their families, announced a $62 million investment from the…